中国组织工程研究 ›› 2022, Vol. 26 ›› Issue (7): 1057-1062.doi: 10.12307/2022.144

• 干细胞基础实验 basic experiments of stem cells • 上一篇    下一篇

黄芩汤调控自噬干预小鼠肠道急性移植物抗宿主病的机制

崔  兴1,孙小琪2,郑  伟1,马德欣2   

  1. 1山东中医药大学附属医院血液科,山东省济南市  250000;2山东中医药大学中医学(八年制),山东省济南市  250000
  • 收稿日期:2020-09-27 修回日期:2020-09-28 接受日期:2020-11-09 出版日期:2022-03-08 发布日期:2021-10-29
  • 通讯作者: 崔兴,博士,副主任医师,山东中医药大学附属医院血液科,山东省济南市 250000
  • 作者简介:崔兴,男,1980年生,山东省济南市人,汉族,2011年山东中医药大学毕业,博士,副主任医师,主要从事血液病临床与实验研究。
  • 基金资助:
    国家自然科学基金(81774080),项目负责人:崔兴;泰山学者计划(tsqn201812145),项目负责人:崔兴;山东省重点研发计划(2019GSF108162),项目负责人:崔兴

Huangqin Decoction regulates autophagy to intervene with intestinal acute graft-versus-host disease in mice

Cui Xing1, Sun Xiaoqi2, Zheng Wei1, Ma Dexin2   

  1. 1Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China; 2Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China
  • Received:2020-09-27 Revised:2020-09-28 Accepted:2020-11-09 Online:2022-03-08 Published:2021-10-29
  • Contact: Cui Xing, MD, Associate chief physician, Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China
  • About author:Cui Xing, MD, Associate chief physician, Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250000, Shandong Province, China
  • Supported by:
    the National Natural Science Foundation of China, No. 81774080 (to CX); the Taishan Scholar Program, No. tsqn201812145 (to CX); the Key Research & Development Plan of Shandong Province, No. 2019GSF108162 (to CX)

摘要:

文题释义:
黄芩汤:出自于《伤寒论》辨太阳病脉证并治第172条,原文为太阳与少阳合病,自下利者,与黄芩汤。黄芩汤以发热口苦、下利急迫、腹痛、肛门灼热、舌苔黄、脉弦数等为应用指征。现代临床黄芩汤用于治疗急性胃肠炎、细菌性痢疾、阿米巴痢疾等。黄芩汤主治病症与胃肠道急性移植物抗宿主病的症状十分相似,因此选用黄芩汤进行实验研究。
肠黏膜屏障:肠上皮细胞是肠黏膜屏障的主体,它与细胞间紧密连接是肠黏膜屏障功能的主要决定者。有证据表明,肠道急性移植物抗宿主病患者治疗后的肠上皮细胞中多种自噬相关蛋白表达明显增高,提示肠上皮细胞发生了自噬。自噬是保护肠黏膜屏障、维持肠道稳态的中药影响因素。
背景:如何应用中药干预肠黏膜屏障损伤后的自噬失衡状态,从而最终干预胃肠道急性移植物抗宿主病的发生是造血干细胞移植后亟需解决的问题。
目的:探讨黄芩汤干预急性肠道移植物抗宿主病的具体机制。
方法:CB6F1小鼠随机分成正常对照组、模型对照组、黄芩汤低剂量组、黄芩汤中剂量组、黄芩汤高剂量组,每组16只。模型对照组及黄芩汤低、中、高剂量组小鼠在60Co全身照射后4 h内(照射总剂量8 Gy),经尾静脉输注Balb/c H-2d小鼠单个核细胞悬液(骨髓细胞8×107/只+脾细胞8×107/只)。造模后当天开始分别给予不同浓度黄芩汤灌胃,模型组及正常对照组灌胃等容量的生理盐水,连续应用15 d。最后一次灌胃后8 h取材,每组取6只小鼠小肠组织,采用PCR和Western blot检测LC3Ⅱ/Ⅰ、Beclin 1、P62表达水平,苏木精-伊红染色进行小肠黏膜病理分级评分,透射电镜观察小肠黏膜上皮细胞自噬泡结构;每组剩余10只(除正常对照组)小鼠进行临床急性移植物抗宿主病分级并记录生存时间。
结果与结论:①应用黄芩汤后,小鼠存活时间显著延长,临床急性移植物抗宿主病评分显著降低,小肠黏膜病理分级评分显著下降,黄芩汤中、高剂量组评分较模型对照组下降最显著,且黄芩汤中、高剂量组之间无显著差异;②模型对照组小鼠小肠组织自噬相关指标LC3Ⅱ/Ⅰ、Beclin 1水平显著低于正常对照组(P < 0.01),P62水平显著高于正常对照组(P < 0.01),黄芩汤可以促进LC3Ⅱ/Ⅰ、Beclin1水平的恢复并下调P62水平(P < 0.01);③透射电镜观察黄芩汤治疗组的自噬泡明显比模型对照组增多,且伴有如线粒体等重要细胞器形态的恢复;④结果表明,黄芩汤通过干预自噬相关蛋白,促进肠道急性移植物抗宿主病自噬稳态的恢复,保护肠黏膜屏障从而减轻了移植后肠道的排异,有望成为治疗急性移植物抗宿主病的新方法。

https://orcid.org/0000-0002-8771-5898(崔兴) 

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

关键词: 骨髓, 脾脏, 单个核细胞, 急性移植物抗宿主病, 黄芩汤, 自噬, 肠黏膜屏障

Abstract: BACKGROUND: How to use traditional Chinese medicine to intervene the imbalance of autophagy after intestinal mucosal barrier injury, so as to ultimately intervene the occurrence of gastrointestinal acute graft-versus-host disease, is an urgent problem to be solved after hematopoietic stem cell transplantation.
OBJECTIVE: To verify the precise mechanism by which Huangqin Decoction interferes with acute intestinal graft-versus-host disease. 
METHODS:  CB6F1 mice were randomly divided into normal control group, model control group, low-dose Huangqin Decoction group, medium-does Huangqin Decoction group and high-does Huangqin Decoction group, with 16 mice per group. CB6F1 mice in the model control group, low-dose Huangqin Decoction group, medium-does Huangqin Decoction group and high-does Huangqin Decoction group were infused with mononuclear cell suspension (bone marrow cell 8×107 + spleen cell 8×107) obtained from Balb/c mice via caudal vein within 4 hours after 60Co whole body irradiation (radiation dose was 8 Gy). Different concentrations of Huangqin Decoction were given by gavage on the same day after modeling. The rats in the model control group and the normal control group were given the same volume of normal saline by gavage for 15 days. Eight hours after the last gavage, the small intestine tissues of six mice in each group were collected. PCR and western blot assay were used to detect the expression levels of LC3II/I, Beclin1 and P62. The pathological grading of small intestinal mucosa was scored by hematoxylin-eosin staining. The autophagic vesicle structure of small intestinal mucosal epithelial cells was observed by transmission electron microscope. The remaining 10 rats in each group (except the normal control group) were used to observe the clinical grading of acute graft-versus-host disease and record the survival time.   
RESULTS AND CONCLUSION: (1) After the application of Huangqin Decoction, the survival time of mice was significantly prolonged; the clinical acute graft-versus-host disease score was significantly decreased, and the pathological grading score of small intestinal mucosa was significantly decreased. The score of medium-does Huangqin Decoction group and high-does Huangqin Decoction group was significantly lower than that of model control group, but there was no significant difference between medium-does Huangqin Decoction group and high-does Huangqin Decoction group. (2) The LC3II/I and Beclin1 expression was significantly lower in the model control group than that in the normal control group (P < 0.01), and P62 expression was significantly higher than that in the normal control group (P < 0.01). Huangqin Decoction could promote the recovery of LC3II/I and Beclin1 levels and downregulate p62 levels (P < 0.01). (3) Under transmission electron microscope, the number of autophagic vesicles in the treatment group was significantly higher than that in the model control group, accompanied by the recovery of important organelles such as mitochondria. (4) The results confirm that by interfering autophagy related proteins, Huangqin Decoction can promote the recovery of autophagy in acute graft-versus-host disease, protect intestinal mucosal barrier and reduce intestinal rejection after transplantation and has promise as a new treatment for acute graft-versus-host disease. 


Key words: bone marrow, spleen, mononuclear cells, acute graft-versus-host disease, Huangqin Decoction, autophagy, intestinal mucosal barrier

中图分类号: